Literature DB >> 11113226

Mechanisms of immunomodulation by glatiramer acetate.

B Gran1, L R Tranquill, M Chen, B Bielekova, W Zhou, S Dhib-Jalbut, R Martin.   

Abstract

OBJECTIVE: To define the mechanism of action of glatiramer acetate (GA; formerly known as copolymer-1) as an immunomodulatory treatment for MS.
BACKGROUND: The proposed mechanisms of action of GA include 1) functional inhibition of myelin-reactive T cells by human leukocyte antigen (HLA) blocking, 2) T-cell receptor (TCR) antagonism, and 3) induction of T helper 2 (Th2) immunomodulatory cells. In this report, the authors examined the effects of GA on the functional activation of human T-cell clones (TCC) specific for myelin basic protein (MBP) and for foreign antigens. Several questions were addressed: Is the inhibitory effect of GA specific for autoantigens? Is it mediated by blocking the interaction between peptide and HLA molecule? Is GA a partial agonist or TCR antagonist, or does it induce anergy? Does it induce Th2 modulatory T cells?
METHODS: The effects of GA on antigen-induced activation of human TCC specific for MBP, influenza virus hemagglutinin, and Borrelia burgdorferi were studied by proliferation and cytokine measurements, TCR downmodulation, and anergy assays. GA-specific TCC were generated in vitro from the peripheral blood of patients and healthy controls by limiting dilution.
RESULTS: GA more strongly inhibited the proliferation of MBP, as compared with foreign antigen-specific TCC; in some MBP-specific TCC, the production of Th1-type cytokines was preferentially inhibited. In addition to HLA competition, the induction of anergy, but not direct TCR antagonism, was observed. Numerous GA-specific TCC were generated from the peripheral blood of both MS patients and normal controls, and a fraction of these showed a Th2 phenotype.
CONCLUSIONS: This study confirms a preferential inhibitory effect of GA on autoreactive TCC. With respect to cellular mechanisms, although HLA competition appears to play the most important role in functional inhibition in vitro, a direct effect on the TCR may be involved at least in some autoreactive T cells as shown by anergy induction. Although not confirmed at the clonal level, it is demonstrated further that GA induces T cells that crossreact with myelin proteins. GA-specific, Th2-modulatory cells may play an important role in mediating the effect of the drug in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11113226     DOI: 10.1212/wnl.55.11.1704

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  27 in total

Review 1.  Degeneracy, as opposed to specificity, in immunotherapy.

Authors:  David A Hafler
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

Review 2.  Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis.

Authors:  Omar Khan; Rana Zabad; Christina Caon; Marina Zvartau-Hind; Alexandros Tselis; Robert Lisak
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 3.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

Review 4.  What do we know about the mechanism of action of disease-modifying treatments in MS?

Authors:  Hans-Peter Hartung; Amit Bar-Or; Yannis Zoukos
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 5.  T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Kate O'Brien; Bruno Gran; Abdolmohamad Rostami
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

6.  Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3.

Authors:  Jian Hong; Ningli Li; Xuejun Zhang; Biao Zheng; Jingwu Z Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-25       Impact factor: 11.205

7.  Methods for the in vitro determination of an individual disposition towards TH1- or TH2-reactivity by the application of appropriate stimulatory antigens.

Authors:  H Barth; P A Berg; R Klein
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

Review 8.  [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Authors:  L Klotz; A Berthele; W Brück; A Chan; P Flachenecker; R Gold; A Haghikia; K Hellwig; B Hemmer; R Hohlfeld; T Korn; T Kümpfel; M Lang; V Limmroth; R A Linker; U Meier; S G Meuth; F Paul; A Salmen; M Stangel; B Tackenberg; H Tumani; C Warnke; M S Weber; T Ziemssen; F Zipp; H Wiendl
Journal:  Nervenarzt       Date:  2016-06       Impact factor: 1.214

9.  Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.

Authors:  D L Arnold; D Campagnolo; H Panitch; A Bar-Or; J Dunn; M S Freedman; S K Gazda; T Vollmer
Journal:  J Neurol       Date:  2008-10-07       Impact factor: 4.849

10.  Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells.

Authors:  Zsolt Illés; Joel N H Stern; Jayagopala Reddy; Hanspeter Waldner; Marcin P Mycko; Celia F Brosnan; Stephan Ellmerich; Daniel M Altmann; Laura Santambrogio; Jack L Strominger; Vijay K Kuchroo
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.